Page last updated: 2024-10-18

dalteparin and Biliary Tract Cancer

dalteparin has been researched along with Biliary Tract Cancer in 2 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Eguchi, H1
Kawamoto, K1
Tsujie, M1
Yukawa, M1
Kubota, M1
Asaoka, T1
Takeda, Y1
Noda, T1
Shimizu, J1
Nagano, H1
Doki, Y1
Mori, M1
Larsen, AC1
Brøndum Frøkjaer, J1
Wishwanath Iyer, V1
Vincents Fisker, R1
Sall, M1
Yilmaz, MK1
Kuno Møller, B1
Kristensen, SR1
Thorlacius-Ussing, O1

Trials

1 trial available for dalteparin and Biliary Tract Cancer

ArticleYear
A Prospective, Multi-Center Phase I Study of Postoperative Enoxaparin Treatment in Patients Undergoing Curative Hepatobiliary-Pancreatic Surgery for Malignancies.
    Digestive surgery, 2020, Volume: 37, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Biliary Tract Neoplasms; Chemoprevention; Digestive

2020

Other Studies

1 other study available for dalteparin and Biliary Tract Cancer

ArticleYear
Venous thrombosis in pancreaticobiliary tract cancer: outcome and prognostic factors.
    Journal of thrombosis and haemostasis : JTH, 2015, Volume: 13, Issue:4

    Topics: Aged; Anticoagulants; Biliary Tract Neoplasms; Dalteparin; Female; Humans; Male; Middle Aged; Pancre

2015